Efficacy of S-1 in patients with castration-resistant prostate cancer: A phase II study

Oncology

Volumn 78, Issue 5-6, 2010, Pages 323-328

  Akaza, Hideyuki ^a   Ikemoto, Isao ^b   Namiki, Mikio ^c   Usami, Michiyuki ^d   Kobayashi, Mikio ^e   Fujimoto, Hiroyuki ^f   Tsukamoto, Taiji ^g   Naito, Seiji ^h  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e Isesaki Municipal Hospital   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

Author keywords

Castration resistant prostate cancer; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; PROSTATE SPECIFIC ANTIGEN; ALANINE AMINOTRANSFERASE; ANTIANDROGEN; ANTINEOPLASTIC ANTIMETABOLITE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONSTIPATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DUODENUM ULCER; FATIGUE; HEART VENTRICLE CONTRACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOTENSION; LEUKOPENIA; MALAISE; MALE; MECONIUM ILEUS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION; BLOOD; BODY SURFACE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG COMBINATION; DRUG TOLERANCE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; ORCHIECTOMY; PATHOLOGY; PROSTATIC NEOPLASMS; SAFETY; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANDROGEN ANTAGONISTS; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG TOLERANCE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ORCHIECTOMY; OXONIC ACID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SAFETY; TEGAFUR; TREATMENT OUTCOME;

EID: 77955287674     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319939     Document Type: Article

References (24)

1. Garcia M JA, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ: Global Cancer Facts and Figures, 2007, pp 16-17.
2. Japan TeboCsi: Cancer Statistics in Japan 2008. Foundation for Promotion of Cancer Research, 2008, pp 52-55.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
5. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-1109.
6. Breul J, Jakse G, Forster G, Lampel A, Rohani A, Hartung R: 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: A prospective randomized pilot trial. Eur Urol 1997; 32: 280-283.
7. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ: The results of a phase ii randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 1995; 153: 1587-1591.
8. Hansen R, Moynihan T, Beatty P, Quebbeman E, Libnoch J, Schulte W, Anderson T: Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 1991; 37: 358-361.
9. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, Kozlowski J, Vogelzang NJ, Blough R, Benson AB 3rd: A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study. Cancer 1993; 72: 1965-1968.
10. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (s-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557.
11. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748-755.
12. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-4009.
13. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with s-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
14. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus s-1 alone for first-line treatment of advanced gastric cancer (spirits trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
15. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with s-1 for gastric cancer. Br J Cancer 2004; 91: 1245-1250.
16. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 1999; 5: 34-40.
17. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994; 12: 2035-2042.
18. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-1670.
19. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
20. Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, Rochlitz C, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP: Capecitabine in hormone-resistant metastatic prostatic carcinoma-a phase II trial. Br J Cancer 2004; 90: 1312-1317.
21. Bhandari MS, Pienta KJ, Fardig J, Olson K, Smith DC: Phase ii trial of oral uracil/tegafur plus leucovorin in patients with hormonerefractory prostate carcinoma. Cancer 2006; 106: 1715-1721.
22. O'Neill VJ, Twelves CJ: Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-937.
23. Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, Nouyrigat P, Foa C, Kaphan R: Phase ii trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006; 107: 738-745.
24. Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, Smith DW, Al Hasan SA, Eliason J: Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 2009; 182: 317-323.